Collagenex, Mutual Settle Patent Suit Over Periodontitis Treatment

Law360, New York (April 10, 2004, 12:00 AM EDT) -- CollaGenex Pharmaceuticals has settled its patent litigation against Mutual Pharmaceuticals over a treatment for adult periodontitis, in an agreement that includes a licensing agreement and a $2 million payment to Mutual.

As part of the settlement, CollaGenex and Mutual entered into a licensing agreement giving Mutual a license to sell a branded version of Periostat. CollaGenex will be the sole supplier of this product to Mutual at prices below CollaGenex's average manufacturer's price through May 2007 or the earlier termination of such supply arrangements due to...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.